Autres langues Arch Therapeutics, Inc.

Actions

ARTH

US03939W2089

Temps Différé OTC Markets Autres places de cotation 16:31:54 03/07/2024			Varia. 5j.	Varia. 1 janv.
0,96 ^USD	+18,52%		0,00%	-86,74%

09/05	Arch Therapeutics, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI
06/05	Arch Therapeutics présentera l'AC5® Advanced Wound System lors du 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Arch Therapeutics, Inc. announced that it has received $0.15 million in funding	12/06
Arch Therapeutics, Inc. announced that it has received $1.85 million in funding	15/05
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	09/05
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	06/05
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	06/05
Arch Therapeutics : New Financial Obligation - Form 8-K	03/04
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	20/02
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	15/02
Arch Therapeutics : New Financial Obligation - Form 8-K	15/12
Arch Therapeutics Provides Year End Operational Update	09/11
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	02/11
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	02/11
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System	13/09/23
Arch Therapeutics Provides AC5® Commercialization Update	13/09/23
Arch Therapeutics Completes Financing as Bridge to Uplisting	08/09/23
Arch Therapeutics, Inc. announced that it has received $2.560063 million in funding	31/08/23
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	11/08/23
Arch Therapeutics, Inc. announced that it expects to receive $1.850001 million in funding	07/07/23
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23/05/23
Arch Therapeutics to Present AC5(R) Advanced Wound System At 2023 Symposium on Advanced Wound Care	25/04/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Arch Therapeutics, Inc.

Actions

ARTH

US03939W2089

Autres langues

Filtres